RDP58 does not prevent graft-versus-host disease after dog leukocyte antigen-nonidentical canine hematopoietic cell transplantation

Transplantation

Volumn 81, Issue 10, 2006, Pages 1460-1462

  Kuhr, Christian S ^a,b   Lupu, Marilena ^a   Little, Marie Térèse ^a   Zellmer, Eustacia ^a   Sale, George E ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Graft versus host disease; Immunosuppressive drugs

Indexed keywords

DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; HLA ANTIGEN CLASS 1; LEUKOCYTE ANTIGEN; METHOTREXATE; PEPTIDE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW APLASIA; CHIMERA; CONDITIONING; CONTROLLED STUDY; DOG; DRUG EFFICACY; EUTHANASIA; GRAFT SURVIVAL; HEAVY CHAIN; HEMATOPOIETIC CELL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WHOLE BODY RADIATION;

ANIMALS; DOGS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; PEPTIDES;

EID: 33744915788     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203323.82681.7d     Document Type: Article

References (23)

1. Storb R, Kolb HJ, Deeg HJ, et al. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplant 1986; 1: 167-177.
2. Storb R, Raff RF, Appelbaum FR, et al. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation 1993; 56: 800-807.
3. Storb R, Deeg HJ, Raff R, et al. Prevention of graft-versus-host disease: studies in a canine model. Ann NY Acad Sci 1995; 770: 149-164.
4. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
5. Storb R, Kolb HJ, Graham TC, et al. Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 1973; 42: 601-609.
6. Lee RS, Kuhr CS, Sale GE, et al. FTY720 does not abrogate acute graft-versus-host disease in the DLA-nonidentical unrelated canine model. Transplantation 2003; 76: 1155-1158.
7. Storb R, Epstein RB, Bryant J, et al. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 1968; 6: 587-593.
8. Storb R, Epstein RB, Graham TC, et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240-246.
9. Kolb HJ, Storb R, Graham TC, et al. Antithymocyte serum and methotrexate for control of graft-versus-host disease in dogs. Transplantation 1973; 16: 17-23.
10. Deeg HJ, Storb R, Weiden PL, et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 1982; 34: 30-35.
11. Yu C, Storb R, Deeg HJ, et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. Bone Marrow Transplantation 1996; 17: 640-653.
12. Grassy G, Calas B, Yasri A, et al. Computer-assisted rational design of immunosuppressive compounds. Nat Biotechnol 1998; 16: 748-752.
13. Iyer S, Kontoyiannis D, Chevrier D, et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000; 275: 17051-17057.
14. Murthy S, Flanigan A, Coppola D, et al. RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflammation Research 2002; 51: 522-531.
15. Piguet PF, Grau GE, Allet B. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987; 166: 1280-1289.
16. Willis D, Moore AR, Frederick R, et al. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 1996; 2: 87-90.
17. Buelow R, Veyron P, Clayberger C, et al. Prolongation of skin allograft survival in mice following administration of ALLOTRAP. Transplantation 1995; 59: 455-460.
18. Li W, Iyer S, Lu L, et al. Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int 2003; 16: 849-856.
19. Gao L, Woo J, Buelow R. Both L- and D-isomers of Allotrap 2702 prolong cardiac allograft survival in mice. J Heart Lung Transpl 1996; 15: 78-87.
20. Murphy B, Kim KS, Buelow R, et al. Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis-Fischer 344 model of chronic allograft rejection. Transplantation 1997; 64: 14-19.
21. Wagner JL, Burnett RC, Works JD, et al. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens 1996; 48: 554-561.
22. Yu C, Ostrander E, Bryant E, et al. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 701-706.
23. Kolb H, Sale GE, Lerner KG, et al. Pathology of acute graft-versus-host disease in the dog: an autopsy study of ninety-five dogs. Am J Pathol 1979; 96: 581-594.